Teva Gets Mixed Ruling in Bid to Block Generic Copaxone

Teva Pharmaceutical Industries Ltd. may face competition to its top-selling multiple sclerosis drug Copaxone a year earlier than analysts expected after a mixed U.S. court ruling on the patents covering the medicine.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.